Loading stock data…
4568.T
TSE¥2,603+103.50 (+4.14%)
Market ClosedLast close Apr 27
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Daiichi Sankyo Company, Limited in the Healthcare sector is trading at ¥2,602. The stock is currently near its 52-week low of ¥2,463, remaining 21.2% below its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why 4568.T maintains its current current market pressure. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price¥2,603
Potential Upside
16%
Whystock Fair Value¥3,018
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target¥4,640+78.3%
Range¥3,050 – ¥6,000
Fundamentals
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or g...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥5.12T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.67
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.17
Div Yield
Strong income play. Yield provides a meaningful total return floor.
274.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.27%
Volume
Today's trading volume
16.62M
Recent News
Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year
Nuvation Bio, Inc. (NYSE:NUVB) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price more than doubled from a year ago, up 156.7%, while it registered a 40.79% increase year-to-date. On April 16, Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio with a price target of […]
5 Best Small-Cap Biotech Stocks According to Hedge Funds
In this article, we will look at the 5 Best Small-Cap Biotech Stocks According to Hedge Funds. Please visit 10 Best Small-Cap Biotech Stocks According to Hedge Funds if you’d like to see an extended list and methodology behind it. 5. Nuvation Bio, Inc. (NYSE:NUVB) Market Cap: $1.76 billion Number of Hedge Fund Holders: 40 […]
Merck’s Priority Review Cancer Drug Adds To Undervalued Growth Story
U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application covers treatment of adult patients with extensive stage small cell lung cancer who have received at least one prior systemic therapy. If approved, ifinatamab deruxtecan could become the first B7-H3 directed therapy in this setting. The therapy is being co-developed by Merck (NYSE:MRK) and Daiichi Sankyo. For investors tracking NYSE:MRK, this Priority Review highlights...
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
The FDA grants priority review to Merck and Daiichi's BLA for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer.
FDA Priority Review And New Alliances Reshape Daiichi Sankyo Growth Story
The FDA has accepted a Priority Review for Daiichi Sankyo and Merck’s biologics license application for ifinatamab deruxtecan in extensive stage small cell lung cancer. If approved, ifinatamab deruxtecan could become the first B7-H3 directed antibody drug conjugate available for cancer treatment. Daiichi Sankyo has entered an APAC R&D alliance with ATLATL and expanded global development of safusidenib through a collaboration with Nuvation Bio. Daiichi Sankyo Company, listed as TSE:4568, is...